Kurzfassung

Clinical first-in-human dose escalation study evaluating the safety and tolerability of intravenous administration of a tetravalent RNA-lipoplex cancer vaccine targeting the tumor-associated antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in patients with advanced melanoma